The effect of sodium‐glucose cotransporter 2 inhibitors on haemoglobin A1c (HbA1c) variability and cardiovascular and renal adverse outcome in patients with T2DM
Authors' conclusion
In patients with high HbA1c variability, SGLT2 inhibitor initiation was associated with superior effectiveness in reducing HbA1c variability compared to DPP-4 inhibitors. The initiation of SGLT2 inhibitors versus DPP-4 inhibitors was linked to significantly reduced cardiovascular and renal adverse events.
Study context
- Population
- Patients with T2DM and HbA1c variability score (HVS) >60% initiating SGLT2i or DPP-4i, Hong Kong, 2015–20221:1 propensity score (PS)-matched
- Exposure
- SGLT2i vs DPP-4i initiation
- SGLT2 inhibitorsn = 4,612
- Outcome
- Post-treatment HVS
- Follow-up
- Within 3 years
Methodological detailsterritory-wide, propensity-score matched (1:1)
- Territory-wide
- Propensity-score matched (1:1)
Main finding
As reported in the abstract
Post-treatment HVS quintile (reference 0%-20%)
SGLT2i vs DPP-4iOdds ratio (95% CI)
HVS 21%-40%
0.76(0.66–0.88)
HVS 41%-60%
0.57(0.50–0.65)
HVS 61%-80%
0.49(0.42–0.56)
HVS 81%-100%
0.40(0.34–0.47)
Observational data: associations, not effects.
Secondary outcomes
| Outcome | HR (95% CI) | |
|---|---|---|
| MACESGLT2ivs DPP-4i | 0.69 (0.60–0.79) | |
| Serious renal events (SRE)SGLT2ivs DPP-4i | 0.71 (0.63–0.80) | |
| 0.512Hazard ratio (log scale) |
Original publication
The effect of sodium‐glucose cotransporter 2 inhibitors on HbA1c variability and cardiovascular and renal adverse outcome in patients with T2DM. Diabetes Obes Metab. Published 13 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →